• China Medical System subsidiary Rxilient Medical secured Singapore approval for ruxolitinib phosphate cream, branded Lumirix, on Nov. 3, 2026.
• The cream treats non-segmental vitiligo with facial involvement in adults and adolescents aged 12 or older.
• Rxilient Medical already sells Lumirix for vitiligo in Hong Kong, Macau and Taiwan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261104-12398422), on November 03, 2026, and is solely responsible for the information contained therein.